Back >>

• Current position:

ESMO 2024 | BlissBio to Present Phase II Clinical Data of ADC BB-1701 at ESMO Congress 2024

Source: | Author:BlissBio | Published time: 2024-09-11 | 1750 Views | Share:

ESMO 2024  |  BlissBio to Present Phase II Clinical Data of ADC BB-1701 at ESMO Congress 2024 

NEWS

September 11, 2024 – BlissBio announces today the Phase II clinical data of antibody-drug conjugate (ADC) BB-1701 will be presented at the European Society for Medical Oncology (ESMO) Congress 2024, which will be held in Barcelona, Spain from September 13 to 17.

Poster Title: A phase 2 study to evaluate the efficacy and safety of BB-1701 in advanced or metastatic NSCLC patients with HER2 mutation/amplification

Poster Board #: 1296P

Session Title: NSCLC, Metastatic

Onsite Poster display date: Saturday, September 14, 2024

At the same meeting, presentations for BB-1701 in previously-treated patients with HER2-positive or HER2-low unresectable or metastatic breast cancer (NCT06188559; Presentation: #437TiP) will also be made by Eisai Co., Ltd. (“Eisai”). 

In 2023, BlissBio and Eisai entered into a clinical trial collaboration for BB-1701, and BlissBio commits to working with Eisai to advance the development of BB-1701 for the benefit of patients worldwide.

About BB-1701

BB-1701 is an innovative ADC developed by BlissBio consisting of anti-HER2 antibody and eribulin. It is designed to provide a safer and more effective treatment regimen for patients with locally advanced/metastatic HER2 expressing solid tumors and expected to have multiple market prospects for application in various tumor indications. BB-1701 has unique mechanism of action (MOA) including potent bystander effect and immunogenic cell death (ICD) activity. BB-1701 is currently in Phase II international clinical trials globally.

Media Inquiries

Bliss Biopharmaceutical Co., Ltd

TEL: +86-0571-86808367

E-mail: office@blissbiopharma.com